Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency for an extension of ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Zenas BioPharma has announced positive findings from its phase 3 INDIGO trial evaluating obexelimab in patients with ...

HUTCHMED has advanced its ongoing study of surufatinib and camrelizumab for treatment‑naïve metastatic pancreatic ductal ...

PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative ...

First long-acting therapy with three-monthly dosing to target root cause of cardiac disease The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending ...

A British inquiry into the use of chemotherapy to treat seriously ill cancer patients has found the treatment caused or hastened death in 27% of cases. A British inquiry into the use of chemotherapy ...

New research highlights NHS approval gap compared to other cancers Research from the Blood Cancer Alliance reveals a significant disparity in access to new blood cancer treatments on the NHS. Between ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s disease and ulcerative colitis (UC). Already used for plaque psoriasis and ...

Foundation’s test to be used in Oxford-led blood biomarker trial The Food for the Brain Foundation’s Cognitive Function Test is set to play a central role in the UK-based ‘READ OUT’ trial, which is ...

Positive safety and pharmacokinetic data lay foundation for phase 2 study in 2026 Herantis Pharma has announced positive topline results from its phase 1b trial of HER-096 in people living with ...

Researchers from University College London (UCL), UCL Hospital (UCLH) and the Francis Crick Institute have revealed that a common drug used to treat cystic fibrosis has been shown to improve outcomes ...